HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA ...
(RTTNews) - Pulse Biosciences Inc. (PLSE), in an update to its recent FDA 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System's current ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...
Sebaceous hyperplasia is most common in middle-aged or older people, particularly those with fair skin who have had a lot sun exposure. There is currently no cure for sebaceous hyperplasia. Some ...
Generally the result of age- related decreases in androgen production, sebaceous hyperplasia is characterized by common asymptomatic papules. The condition occurs most frequently in healthy ...
CASE #2: Sebaceous hyperplasia Sebaceous hyperplasia (SH) is the physical manifestation of enlargement of the sebaceous gland to the point where discrete raised yellow aggregations of cells can be ...
Please provide your email address to receive an email when new articles are posted on . Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results